Companies › Absci
1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ABS-201 IgG1 monoclonal antibody targeting prolactin receptor (PRLR) | PRLR | Phase 1 | Androgenetic Alopecia (AGA) | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07317544 | ABS-201 | Phase 1 | Androgenetic Alopecia (AGA) | Immunology | Jul 2028 |
Cash and short-term investments of $201m on 2026-06-30; operating cash outflow about $109m a year; runway about 22 months at that burn, to May 2028
Press releases filed as 8-K in the last year:
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.